<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>There is a significant amount of morbidity and mortality following myeloablative umbilical cord blood transplantation (UCBT) </plain></SENT>
<SENT sid="1" pm="."><plain>Reduced intensity (RI) conditioning offers an alternative to myeloablative conditioning before UCBT </plain></SENT>
<SENT sid="2" pm="."><plain>We investigated RI-UCBT in 21 children and adolescents with malignant (n=14), and non-malignant diseases (n=7) </plain></SENT>
<SENT sid="3" pm="."><plain>RI conditioning consisted of fludarabine (150-180 mg/m2) with either <z:chebi fb="0" ids="28901">busulfan</z:chebi> (&lt; or = 8 mg/kg)+rabbit antithymocyte globulin (R-ATG; n=16) or <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>+R-ATG+/-<z:chebi fb="0" ids="4911">etoposide</z:chebi> (n=5) </plain></SENT>
<SENT sid="4" pm="."><plain>Human leukocyte antigen match: 4/6 (n=13), 5/6 (n=5) and 6/6 (n=3) </plain></SENT>
<SENT sid="5" pm="."><plain>The median total nucleated cell and CD34+ cell dose per kilogram were 3.58 x 10(7) and 2.54 x 10(5), respectively </plain></SENT>
<SENT sid="6" pm="."><plain>The median time for neutrophil and platelet engraftment was 17.5 and 52 days, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>There were six primary graft failures (<z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), <z:e sem="disease" ids="C0005283" disease_type="Disease or Syndrome" abbrv="">beta-thalassemia</z:e>, <z:e sem="disease" ids="C0024291" disease_type="Disease or Syndrome" abbrv="">hemophagocytic lymphohistiocytosis</z:e> (HLH) and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>)) </plain></SENT>
<SENT sid="8" pm="."><plain>The probability of developing grade II to grade IV <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) and <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD was 28.6 and 16.7%, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>Incidence of transplant-related mortality (TRM) was 14% </plain></SENT>
<SENT sid="10" pm="."><plain>The 5 years overall survival (OS) in <z:hpo ids='HP_0000001'>all</z:hpo> patients was 59.8% </plain></SENT>
<SENT sid="11" pm="."><plain>The 5 years OS for patients with average versus poor-risk <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> was 77.8 versus 22.2% (P=0.03) </plain></SENT>
<SENT sid="12" pm="."><plain>RI-UCBT may result in graft failure in specific high-risk chemo-na√Øve patients (<z:mp ids='MP_0005481'>CML</z:mp>, <z:e sem="disease" ids="C0005283" disease_type="Disease or Syndrome" abbrv="">beta-thalassemia</z:e>, HLH and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), but in more heavily pretreated pediatric and adolescent recipients results in rapid engraftment and may be associated with decreased severe GVHD and TRM </plain></SENT>
</text></document>